Evidence map›Paper›PMID 31227699›Full record

Observational studyNature communications2019

HIV-1 DNA sequence diversity and evolution during acute subtype C infection.

Guinevere Q Lee, Kavidha Reddy, Kevin B Einkauf, Kamini Gounder, Joshua M Chevalier, Krista L Dong, Bruce D Walker, Xu G Yu, Thumbi Ndung'u, Mathias Lichterfeld

Abstract readObservational Study
In one paragraph

Observational study in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Immortalization and Targeted Enrichment of HIV-Infected CD4International journal of molecular sciences · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Guinevere Q LeeRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0002-9412-886X
Kavidha ReddyHIV Pathogenesis Programme, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, 4001, South Africa.ORCID http://orcid.org/0000-0002-7024-0574
Kevin B EinkaufRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0001-7123-1293
Kamini GounderHIV Pathogenesis Programme, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, 4001, South Africa.
Joshua M ChevalierRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0001-8873-6669
Krista L DongRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Bruce D WalkerRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0001-6122-9245
Xu G YuRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Thumbi Ndung'uRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0003-2962-3992
Mathias LichterfeldRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA. MLICHTERFELD@mgh.harvard.edu.

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
A Pilot Clinical Trial for HIV-1 EradicationU01AI117841 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2015 to 2020
$10.7M
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in BotswanaU01AI135940 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2018 to 2024
$10.4M
Pathogenesis of Clade C HIV InfectionR37AI067073 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2011 to 2020
$6.6M
Early Infant TreatmentU01AI114235 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2014 to 2020
$5.1M
Molecular profile of proviral reservoirs in HIV-infected drug usersR61DA047034 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LICHTERFELD, MATHIAS, YU, XU · 2018 to 2020
$3.4M
A systems biology approach to fingerprint HIV immune defense in Elite ControllersR01HL134539 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2016 to 2019
$3.3M
Proteomics and phosphoproteomics analysis in HIV-1 infectionR01AI130005 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LICHTERFELD, MATHIAS · 2017 to 2021
$2.9M
Molecular profile of proviral reservoirs in HIV-infected drug usersR33DA047034 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LICHTERFELD, MATHIAS, YU, XU · 2022 to 2024
$2.0M
Quantification of the HIV-1 Reservoir by Immuno-PCRR01AI120008 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI HEREDIA, ALONSO, LICHTERFELD, MATHIAS · 2015 to 2019
$1.9M
Targeting HIV-1 persistence with Interferon-aR33AI116228 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2016 to 2018
$1.5M
Preclinical Development of Ingenol and HDACi Toward HIV EradicationR33AI122377 · NIAID · UNIVERSITY OF UTAH · PI PLANELLES, VICENTE · 2018 to 2020
$1.1M
NHLBI NIH HHS R01 HL134539NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI120008NIAID NIH HHS R01 AI130005NIAID NIH HHS R21 AI116228NIAID NIH HHS R21 AI122377NIAID NIH HHS R21 AI124776NIAID NIH HHS R33 AI116228NIAID NIH HHS R33 AI122377NIAID NIH HHS R37 AI067073NIAID NIH HHS U01 AI114235NIAID NIH HHS U01 AI117841NIAID NIH HHS U01 AI135940NIDA NIH HHS R33 DA047034NIDA NIH HHS R61 DA047034Wellcome Trust
6 · The paper itself

Abstract

Little is known about the genotypic make-up of HIV-1 DNA genomes during the earliest stages of HIV-1 infection. Here, we use near-full-length, single genome next-generation sequencing to longitudinally genotype and quantify subtype C HIV-1 DNA in four women identified during acute HIV-1 infection in Durban, South Africa, through twice-weekly screening of high-risk participants. In contrast to chronically HIV-1-infected patients, we found that at the earliest phases of infection in these four participants, the majority of viral DNA genomes are intact, lack APOBEC-3G/F-associated hypermutations, have limited genome truncations, and over one year show little indication of cytotoxic T cell-driven immune selections. Viral sequence divergence during acute infection is predominantly fueled by single-base substitutions and is limited by treatment initiation during the earliest stages of disease. Our observations provide rare longitudinal insights of HIV-1 DNA sequence profiles during the first year of infection to inform future HIV cure research.

Indexed as

Evolution, MolecularAcute DiseaseAdultAnti-HIV AgentsDNA Mutational AnalysisDNA, ViralFemaleFollow-Up StudiesGenome, ViralHigh-Throughput Nucleotide SequencingHIV-1HIV InfectionsHumansLongitudinal StudiesMutationProspective StudiesAnti-HIV AgentsDNA, Viral

Identifiers

PMID31227699
PMCPMC6588551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.